Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Brenda and our expert team do not believe in one-size-fits-all solutions
Retatrutide (LY3437943): Educational Overview Executive Summary Retatrutide is an investigational triple-agonist incretin therapy activating: GLP-1 receptors GIP receptors glucagon receptors This multi-pathway engagement affects: appetite regulation insulin signaling lipid metabolism hepatic glucose handling energy expenditure References: Coskun T et al., Cell Metabolism , 2022 Jastreboff AM et al., NEJM , 2023 Mechanism of Action GLP-1 Receptor Activation GLP-1 signaling: increases glucose-dependent insulin secretion slows gastric emptying activates satiety pathways in the brain Reference: Drucker DJ, Cell Metabolism , 2018 GIP Receptor Activation GIP signaling: enhances insulin secretion improves adipocyte insulin sensitivity modulates lipid metabolism References: Finan B et al., Nature Medicine , 2013 Nauck MA et al., Diabetes Care , 2021 Glucagon Receptor Activation Retatrutide uniquely activates glucagon receptors
J., Dreher, F., & Maibach, H
Wegovy is for obesity and related health issues
Your first-month weight loss trajectory on compounded semaglutide is clinically equivalent to Wegovy because the active ingredient, injection technique, and dosing schedule remain identical
US$ 28.53
US$ 21.63
US$ 20.27
US$ 21.63
US$ 23.74
US$ 26.13
US$ 27.67
US$ 24.69
US$ 20.45
US$ 22.82
US$ 28.45
US$ 21.56
